<DOC>
	<DOCNO>NCT02542605</DOCNO>
	<brief_summary>Phase I , Randomized , Parallel-group , Double-Blind , Placebo-Controlled , Single Dose Study Evaluate Blockade CGRP Receptor AMG 334 Preventing PACAP-38 Induced Migraine-like Attacks Migraine Patients .</brief_summary>
	<brief_title>To Evaluate Blockade CGRP Preventing PACAP-38 Induced Migraine-like Attacks With AMG 334 Migraine Patients</brief_title>
	<detailed_description />
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>Pituitary Adenylate Cyclase-Activating Polypeptide</mesh_term>
	<criteria>Adults ≥ 18 ≤ 45 year age upon entry screen History migraine headache without aura ≥ 6 month prior screen accord IHS Classification ICHDII ( Headache Classification Committee International Headache Society , 2004 ) base medical record and/or patient selfreport Migraine frequency : ≥ 1 ≤ 5 migraine day per month 3 month prior screen History migraine aura , cluster headache hemiplegic migraine headache accord IHS Classification ICHDII ( Headache Classification Committee International Headache Society , 2004 ) base medical record and/or patient selfreport ≥ 6 migraine day per month last 3 month prior study enrollment screening period Other headache disorder ( except episodic tensiontype headache &lt; 5 days/month )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Migraine</keyword>
	<keyword>Headache</keyword>
	<keyword>Migraine Headache</keyword>
	<keyword>Headache , Migraine</keyword>
	<keyword>Amgen</keyword>
</DOC>